Gynoflor (Estriol, Lactobacillus Acidophilus)

Gynoflor is indicated for the local treatment of estrogen deficiency in the vaginal tissue. It is commonly used to relieve symptoms associated with vulvovaginal atrophy in postmenopausal women.

• Relief of vaginal dryness and irritation caused by low estrogen levels.
• Reduction of itching, burning, and discomfort during intercourse.
• Restoration of normal vaginal epithelium thickness and elasticity.
• Re‑establishment of a Lactobacillus‑dominant vaginal flora.
• Management of mild urinary symptoms related to genitourinary syndrome of menopause.

Side effects reported with Gynoflor are generally mild and related to its local estrogen and probiotic components.

Common

• Mild vaginal spotting or spotting after application.
• Temporary increase in vaginal discharge, often white or clear.
• Mild irritation or burning sensation at the site of insertion.
• Transient abdominal cramping or pelvic discomfort.

Serious

• Signs of systemic estrogen exposure such as breast tenderness.
• Unexplained vaginal bleeding or heavy bleeding.
• Allergic reaction including rash, swelling, or difficulty breathing.
• Development of endometrial hyperplasia with prolonged use (rare).

Before using Gynoflor, certain health considerations should be reviewed to ensure safe and appropriate therapy.

• Not recommended for women with known estrogen‑dependent tumors (e.g., breast or endometrial cancer).
• Use with caution in patients with a history of thromboembolic disorders.
• Avoid if active vaginal infection or untreated sexually transmitted infection is present.
• Do not use during pregnancy or while breastfeeding unless advised by a clinician.
• Monitor for persistent vaginal bleeding and report to a healthcare provider.
• Consider bone health status, as systemic absorption, though low, may occur with long‑term use.

Gynoflor may interact with other medications or products that influence estrogen activity or vaginal environment.

Avoid

• Systemic hormone replacement therapy or oral contraceptives that contain estrogen, which may increase overall estrogen exposure.
• Antifungal or antibacterial vaginal preparations applied simultaneously, which could reduce probiotic viability.

Use with caution

• Anticoagulant drugs (e.g., warfarin) because estrogen can affect clotting factors.
• Selective estrogen receptor modulators (SERMs) that have opposing estrogen actions.
• Systemic corticosteroids, which may alter mucosal healing.
• Herbal supplements with estrogenic activity such as black cohosh or phytoestrogens.